Cyclooxygenase-2 (COX-2) is the enzyme primarily responsible for prostaglandin synthesis
in the setting of inflammation. It also can be induced by a variety of agents, including tumor …

Tumorigenesis is a complex process, and understanding the mechanisms behind
tumorigenesis is key to identifying effective targeted therapies. Prostaglandins are signaling …

Prior to the discovery of cyclooxygenase-2 (COX-2), a beneficial association was shown
between chronic usage of non steroidal anti-inflammatory drugs (NSAIDs), that …

Cyclooxygenase (COX) inhibitors are being developed as potential agents for the
prevention and treatment of cancer after a century of widespread use for inflammation, fever …

By inhibiting the cyclooxygenase (COX) enzyme, NSAIDs block the synthesis of
prostaglandins, which are important mediators of multiple physiologic and pathophysiologic …

Cyclooxygenase-2 (COX-2) is being intensively evaluated as a pharmacologic target for
both the prevention and treatment of cancer. Aberrant COX-2 expression was initially …

Despite recent improvements in chemotherapy and radiation therapy in cancer management
with the addition of biological agents, novel treatment approaches are needed to further …

The discovery of the isoenzymes cyclooxygenase (COX-) 1 and COX-2 led to the
development of newer nonsteroidal anti-inflammatory drugs (NSAIDs) designed to block …

Tumor growth and angiogenesis are interdependent. Cyclooxygenase (COX) catalyzes the
synthesis of prostaglandins (PGs) from arachidonic acid. Nonsteroidal antiinflammatory …

Several lines of evidence suggest that the cyclooxygenase enzymes (specifically COX-2)
might be an important molecular target for the intervention of cancer at both early and late …